Literature DB >> 8539339

Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression.

D H Overstreet1, O Pucilowski, A H Rezvani, D S Janowsky.   

Abstract

Flinders Sensitive Line (FSL) rats have been proposed as an animal model of depression because they resemble depressed humans in that they have elevated REM sleep, reduced activity, and increased immobility and anhedonia after exposure to stressors. The present paper reviews experiments on the drug treatment of FSL and control Flinders Resistant Line (FRL) rats related to their utility as an animal model of depression, and presents new information. FSL rats exhibited exaggerated immobility in the forced swim test which is counteracted by the tricyclic antidepressants imipramine and desipramine and the serotonin reuptake blocker sertraline; the low immobility exhibited by the FRL rats is generally unaffected by these compounds. In contrast to these "therapeutic" effects of well recognized antidepressants, lithium and bright light treatment did not alter the exaggerated immobility of FSL rats. Novel data indicated that neither FSL nor FRL rats exhibited alterations in swim test immobility following chronic administration of the psychomotor stimulant amphetamine (2 mg/kg) and the anticholinergic scopolamine (2 mg/kg), which typically reduce immobility after acute administration. However, it was found that the calcium channel blockers verapamil (5 and 15 mg/kg) and nicardipine (10 mg/kg) did reduce the exaggerated immobility in FSL rats following chronic administration, suggesting that these compounds need to be evaluated further in humans. Previous studies have indicated no differences between FSL and FRL rats evaluated in the elevated plus maze, either at baseline or after the administration of diazepam, suggesting that the FSL rat may not differ from controls in anxiety-related behavior. Another recently published study showed that the FSL rat also did not differ from normal Sprague-Dawley rats in startle tests, indicating that the FSL rats do not exhibit behaviors shown in animal models of schizophrenia. These findings confirm the utility of FSL rats as an animal model of depression because the FSL rats do not appear to exhibit behaviors analogous to anxiety or schizophrenia and because they respond "therapeutically" to antidepressants and not psychomotor stimulants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8539339     DOI: 10.1007/bf02245589

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  77 in total

Review 1.  Do calcium antagonists have a place in the treatment of mood disorders?

Authors:  C Höschl
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Tolerance to low acetylcholinesterase levels: modification of behavior without acute behavioral change.

Authors:  T J Chippendale; G A Zawolkow; R W Russell; D H Overstreet
Journal:  Psychopharmacologia       Date:  1972

3.  Flinders resistant hypocholinergic rats exhibit startle sensitization and reduced startle thresholds.

Authors:  A Markou; K Matthews; D H Overstreet; G F Koob; M A Geyer
Journal:  Biol Psychiatry       Date:  1994-11-15       Impact factor: 13.382

4.  The effects of Ca2+ antagonists and hydralazine on central 5-hydroxytryptamine biochemistry and function in rats and mice.

Authors:  A R Green; R J DeSouza; E M Davies; A J Cross
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 5.  Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia.

Authors:  R Tandon; J F Greden
Journal:  Arch Gen Psychiatry       Date:  1989-08

6.  Defensive burying behavior in maudsley reactive (MR/Har) and nonreactive (MNRA/Har) rats.

Authors:  S L Beardslee; E Papadakis; H J Altman; G M Harrington; R L Commissaris
Journal:  Physiol Behav       Date:  1989-02

7.  Acute and chronic effects of serotonin (5HT) antagonists on serotonin binding sites.

Authors:  M A Blackshear; R L Friedman; E Sanders-Bush
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

8.  Swim test immobility co-segregates with serotonergic but not cholinergic sensitivity in cross-breeds of Flinders Line rats.

Authors:  D H Overstreet; D S Janowsky; O Pucilowski; A H Rezvani
Journal:  Psychiatr Genet       Date:  1994       Impact factor: 2.458

9.  Spatial working and reference memory in rats bred for autonomic sensitivity to cholinergic stimulation: acquisition, accuracy, speed, and effects of cholinergic drugs.

Authors:  P J Bushnell; E D Levin; D H Overstreet
Journal:  Neurobiol Learn Mem       Date:  1995-03       Impact factor: 2.877

10.  Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists.

Authors:  M J Detke; S Wieland; I Lucki
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

View more
  19 in total

1.  Nicotine as a typical drug of abuse in experimental animals and humans.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-10-05       Impact factor: 4.530

2.  A selective test for antidepressant treatments using rats bred for stress-induced reduction of motor activity in the swim test.

Authors:  Charles Hutchison Keesor West; Jay Michael Weiss
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

3.  Decoding of dopaminergic mesolimbic activity and depressive behavior.

Authors:  Alexander Friedman; Ilana Deri; Yaakov Friedman; Eliyahu Dremencov; Sophia Goutkin; Elizabeth Kravchinsky; Matti Mintz; Dino Levi; David H Overstreet; Gal Yadid
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 4.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Expression profiling of a genetic animal model of depression reveals novel molecular pathways underlying depressive-like behaviours.

Authors:  Ekaterini Blaveri; Fiona Kelly; Alessandra Mallei; Kriss Harris; Adam Taylor; Juliet Reid; Maria Razzoli; Lucia Carboni; Chiara Piubelli; Laura Musazzi; Girogio Racagni; Aleksander Mathé; Maurizio Popoli; Enrico Domenici; Stewart Bates
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

6.  Nerve growth factor (NGF) has novel antidepressant-like properties in rats.

Authors:  David H Overstreet; Kellie Fredericks; Darin Knapp; George Breese; John McMichael
Journal:  Pharmacol Biochem Behav       Date:  2009-11-27       Impact factor: 3.533

7.  Both acute and chronic buspirone treatments have different effects on regional 5-HT synthesis in Flinders Sensitive Line rats (a rat model of depression) than in control rats.

Authors:  Kyoko Nishi; Kazuya Kanemaru; Shu Hasegawa; Arata Watanabe; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-25       Impact factor: 3.921

Review 8.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

9.  Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents.

Authors:  Yukihiko Shirayama; Shigeyuki Chaki
Journal:  Curr Neuropharmacol       Date:  2006-10       Impact factor: 7.363

10.  Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine.

Authors:  Andréy Mazarati; Prabha Siddarth; Roger A Baldwin; Don Shin; Rochelle Caplan; Raman Sankar
Journal:  Brain       Date:  2008-06-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.